From biorefineries to consumer goods
More than 400 experts came together at the World Bio Market Conference in Amsterdam to discuss the challenges of successfully implementing bio-based business strategies.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2209 entries already.
Entries by Thomas Gabrielczyk
Ablynx’ SLE antibody vobarilizumab miss endpoint
Belgian nanobody maker Ablynx’ IL-6 receptor blocker vobarilizumab didn’t met the primary endpoint of dose response at 24 weeks in a Phase II study enroling 312 patients with severe, active seropositive systemic lupus erythematosus (SLE).
MorphoSys files registration for ADS offering
Antibody specialist MorphoSys AG has filed a Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission (SEC) for a proposed Nasdaq offering of American Depositary Shares (ADS)
Biotech for breaking down a sea of waste
While bio-based polymers have been a hot topic for some years now, it’s grown increasingly clear that where plastics end up is at least as important as how they’re made. Current recycling technologies are limited, bringing either low-quality recyclates or high processing costs. But enzymes now offer a glimmer of hope. Working with the common plastic PET, a French firm is trying to prove biotech approaches can close the loop in the material’s life cycle. They hope they’ll soon be able to recycle the plastic endlessly and affordably.
Deinove to licence antibiotic leads form RedX Pharma
French antibiotics player Deinove has inked a licence option agreement with Redx Pharma plc concerning a new class of synthetic preclinical topoisomerase blockers to treat infections caused by Gram-negative ESKAPE pathogens.
Bioeconomy: Germany to lose pole position
The German Bioeconomy Council said policymakers would risk Germany’s leadership in bioeconomy if they don’t capitalise on new technology options resulting from the ongoing merger of digital and bio-technologies.
Eylea met Phase III endpoint in diabetic retinopathy
VEGF blocker Eylea (aflibercept), which is co-developed for eye diseases by Bayer HealthCare and Regeneron under a deal signed in 2006, has met the 24-week primary endpoint of the pivotal Panorama Phase III trial.
Lundbeck acquiring Prexton in €905m deal
H. Lundbeck A/S has announced it will acquire Dutch Prexton Therapeutics B.V., a one-programme company developing the allosteric metabotropic glutamate receptor subtype 4 (mGluR4) modulator foliglurax (PXT002331) in Parkinson’s Disease.
Stroke alarmin spurs further embolies
Researchers from Sweden, Switzerland, France, Italy, and Germany report that expression of a post-stroke factor boost arterial plaque formation. The identification of the new target might open up an avenue to prevent embolism and further complications in stroke patients.
Making an impact on AMR R&D
At the 11th Berlin Conference, Novo Holdings outlined details of a new €135m investment fund launched to push the development of new drug classes urgently needed to fight antimicrobial resistance. European Biotechnology editors were the first to talk with Aleks Engel, Partner at Novo Holdings, and George Griffin, Chair of the Repair Impact Fund’s Scientific Advisory Board, about the construction and the goal of the fund.